In recent years, blockbuster drugs, such as semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro), and liraglutide (Victoza), have received growing attention as promising drugs for the treatment of type 2 diabetes and obesity .

Known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), these drugs mimic the natural hormone GLP-1, which binds to and activates GLP-1 receptors in the brain and gastrointestinal tract, regulating blood sugar levels and reducing food intake.

Now, researchers at Duke University School of Medicine, in Durham, North Carolina, have discovered a new form of blood sugar regulation, which opens up new avenues to treating type 2 diabetes.

In their study, published in the journal Science Advances and titled “α cells use both PC1/3 and PC2 to process p

See Full Page